Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Mucosal Immunology|April 13, 2025
A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-upVancheswaran Gopalakrishnan, Chanchal Kumar, Ida Robertsen, et al.
World Journal of Gastroenterology|September 24, 2019
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat sourceMichelle L Boland, Denise Oró, Kirstine S Tølbøl, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic MiceRoger V Ortines, Haiyun Liu, Lily I Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 14, 2017
Mouse model of hematogenous implant-related <i>Staphylococcus aureus</i> biofilm infection reveals therapeutic targetsYu Wang, Lily I Cheng, David R Helfer, et al.
JCI Insight|September 7, 2018
Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targetsJohn M Thompson, Robert J Miller, Alyssa G Ashbaugh, et al.
Science Advances|March 6, 2021
PD-L1<sup>+</sup> neutrophils contribute to injury-induced infection susceptibilityAjitha Thanabalasuriar, Abby J Chiang, Christopher Morehouse, et al.
Mbio|October 13, 2025
Alpha-toxin-elicited CX<sub>3</sub>CL1 release in <i>Staphylococcus aureus</i> pneumonia impairs bactericidal function of human monocytesSrikanth Mairpady Shambat, Puran Chen, Rocky M Barilla, et al.
Blood|May 19, 2026
TGFβ-PDL1 signaling in neutrophils preserves lung barrier during hyperinflammationZiyi Li, Andrew Reese Moore, Hong Zheng, et al.
The Lancet. Infectious Diseases|February 27, 2025
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trialGhady Haidar, Steven Thomas, Paul Loubet, et al.
Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
Pageof 6